Special Issue "Th17 Cell in Autoimmune and Inflammatory Diseases"
Deadline for manuscript submissions: closed (30 April 2017).
Interests: immunology, especially IL-17 and Th17, and bone cell biology, especially osteoclasts, in the pathogenesis of rheumatoid arthritis
The Th17 cell has become the most exiting field, not only in basic, but also clinical immunology. Th17 cells play an important role in bone cell biology. The anti-IL-17 antibody shows an effect on ankylosing spondylitis, non-radiographic axial spondylitis, psoriasis, and psoriatic arthritis. In therapy for rheumatoid arthritis (RA), anti-IL-17 antibody did not show enough effect in clinical trials. Recently, however, two meta-analysis reports demonstrated that the anti-IL-17 antibody is effective in ameliorating RA symptoms. Bi-specific antibodies, against both IL-17 and TNF-alpha, have shown effects on the activities of rheumatoid arthritis. In addition, the plasticity of Th17 is currently being investigated in basic and clinical immunology. The field of IL-17 and Th17 cells has moved very quickly, from bench to bedside or bedside to bench. Thus, please join us in presenting this Special Issue on the state-of-the-art research currently being performed worldwide, to investigate IL-17 and Th17, in order to help understand and treat various human autoimmune and inflammatory diseases.
Dr. Shigeru Kotake
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Th17 cell
- rheumatoid arthritis
- bispecific antibody